John Flavin - Oct 7, 2021 Form 3 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for John Flavin
Stock symbol
PYXS
Transactions as of
Oct 7, 2021
Transactions value $
$0
Form type
3
Date filed
10/7/2021, 09:21 PM
Next filing
Oct 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PYXS Common Stock 169K Oct 7, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PYXS Series B Convertible Preferred Stock Oct 7, 2021 Common Stock 2.39K Direct F2
holding PYXS Stock Option (Right to buy) Oct 7, 2021 Common Stock 15.7K $8.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date.
F2 Each 6.359 shares of Series B Convertible Preferred Stock are currently convertible into one share of Common Stock at the option of the holder, for no additional consideration, and will convert automatically upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). These shares have no expiration date.
F3 These stock options vest in three, substantially-equal annual installments beginning on the first anniversary of the August 19, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney